Clinical trials: Acute Myelogenous Leukemia (AML)
Acute Myeloid Leukemia, Acute Myeloid Leukemia, Adult
Feasibility and Efficiency Study for the Implementation of a New Screening Method for Patients With Acute Myeloid Leukemia, in Laboratory Practice
Prospective, multicenter study for the non-inferiority assessment of RAMD compared to GSS in determining the prognostic risk category according to ELN2022 for newly diagnosed AML patients on blood samples.
- Conditions
- Acute Myeloid Leukemia, Acute Myeloid Leukemia, Adult, Acute Promyelocytic Leukemia
- Trial name
- RAMD (NCT07867704)
- Testing
- Bone marrow or peripheral blood withdrawal for test comparison
- Volunteers
- 75 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Myelodysplastic Syndromes, Acute Myeloid Leukemia
Efficiency of Antibacterial Prophylaxis in Azacitidine Treated Patients
Infections are a major life-threatening complication in patients with myelodysplastic syndrome (MDS) or acute myeloid leukaemia (AML).
- Trial name
- AZABAC (NCT03594149)
- Testing
- Levofloxacin
- Where
- 4 sites in France
- Volunteers
- 60 people
- Sponsor
- Centre Henri Becquerel
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Monitoring Minimal Residual Disease of Patients With Acute Myelogenous Leukemia or High Grade Myelodysplastic Syndrome
This study is being performed to develop assays to determine the impact of the therapy patients receive for treatment of AML or MDS and to determine if these tests can identify those patients who are at a greater risk for having…
- Trial name
- MRD (NCT01311258)
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- University of Rochester
Pulmonary Aspergillosis - Invasive, Acute Myeloid Leukemia
Study on Safety and Pharmacokinetics of Intravenous F901318 for Fungal Prophylaxis in AML Patients
This study assesses the pharmacokinetics and safety of the new antifungal F901318 in AML patients.
- Trial name
- SAFEGUARD (NCT02856178)
- Testing
- F901318, Caspofungin
- Sponsor
- F2G Ltd
NPMc+ AML
Oral Arsenic Trioxide for NPM1-mutated AML
A prospective open-label phase 2 study will be designed to assess the efficacy of oral arsenic trioxide plus azacitidine in preventing relapses in patients with NPM1-mutant AML.
- Trial name
- NCT04689815
- Testing
- Oral Arsenic Trioxide Formulation
- Where
- Hong Kong
- Volunteers
- 50 people
- Sponsor
- The University of Hong Kong
AML, Adult
Avapritinib Maintenance for AML With KIT Mutations
A multicenter, single-arm clinical study of evaluate the efficacy and safety of avapritinib as maintenance therapy following allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia patients with KIT mutation.
- Trial name
- NCT06765915
- Testing
- Avapritinib
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Ruijin Hospital
Acute Myeloid Leukemia
Venetoclax + Cytarabine Versus Idarubicin + Cytarabine : Efficacity Assessment as Post-remission Therapy to Elderly Patients With Acute Myeloid Leukemia in First Remission
For the FILO group, the standard of care for induction chemotherapy of elderly fit patients with AML is represented by the combination of Cytarabine, Idarubicin and Lomustine.
- Trial name
- LAMSA2020 (NCT04968015)
- Testing
- Cytarabine-Venetoclax Association, Cytarabine-Idarubicin Association
- Where
- 26 sites in France
- Volunteers
- 134 people
- Sponsor
- French Innovative Leukemia Organisation
Acute Myeloid Leukemia
Diagnostic Platform to Perform Centralized and Standardized Rapid Molecular Diagnosis by Next Generation Sequencing (NGS) in Patients Diagnosed With Acute Myeloid Leukemia.
NGS studies will be done in stem cell leukemic population. The analysis of the samples to the diagnosis will be carried out using the 26 consensus genes: ASXL1 had, CBL, CEBPA, DNMT3A, EZH2, FLT3, GATA2, IDH1, IDH2, JAK2, KIT…
- Trial name
- NCT03311815
- Testing
- NGS techniques
- Where
- 7 sites in Spain
- Volunteers
- 900 people
- Sponsor
- PETHEMA Foundation
Acute Myelogenous Leukemia, Myelodysplastic Syndromes
Dose Escalation of OXi4503 as Single Agent and Combination With Cytarabine w/Subsequent Ph 2 Cohorts for AML and MDS
Phase 1 will investigate maximum tolerated dose of OXi4503 as a single agent and in combination with intermediate-dose cytarabine in subjects with relapsed/refractory AML or MDS.
- Trial name
- AML (NCT02576301)
- Testing
- Phase 1 - OXi4503, Phase 1 - OXi4503 + cytarabine, Phase 2 - OXi4503 + cytarabine
- Where
- 4 sites in United States
- Volunteers
- 105 people
- Sponsor
- Mateon Therapeutics
CD123+ Acute Myeloid Leukemia
Study of ORM-1153 in Acute Myeloid Leukemia (AML) With CD123 Expression
The goal of this Phase 1 clinical trial is to understand whether a new experimental treatment, called ORM-1153, will be a safe and possibly effective treatment option for participants with blood cancers such as Acute Myeloid…
- Trial name
- NCT07809906
- Testing
- ORM-1153
- Where
- 2 sites in United States
- Volunteers
- 42 people
- Sponsor
- Orum Therapeutics USA, Inc.
Brain and Central Nervous System Tumors, Leukemia
Talotrexin in Treating Young Patients With Recurrent Solid Tumors or Leukemia That is Recurrent or Does Not Respond to Treatment
RATIONALE: Drugs used in chemotherapy, such as talotrexin, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Brain and Central Nervous System Tumors, Leukemia, Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific
- Trial name
- NCT00458744
- Testing
- talotrexin, chemotherapy
- Sponsor
- Children's Oncology Group
Acute Myeloid Leukemia
Clinical Study of Venetoclax Combined With CAG in the Treatment of Refractory/Relapsed Acute Myeloid Leukemia
The goal of this clinical trial is to test the safety and efficacy of venetoclax plus CAG regimen in refractory/relapsed acute myeloid leukemia patients.
- Trial name
- NCT05918198
- Testing
- Ven+CAG
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Peking University People's Hospital
Cancer
Study of Information Received About Fertility and Infertility in Patients Who Have Finished Treatment for Cancer
RATIONALE: Learning about the amount of information on fertility and infertility by patients before they received treatment for cancer in a comprehensive cancer center may help doctors plan the best treatment.
- Trial name
- NCT01295463
- Testing
- questionnaire administration, study of socioeconomic and demographic variables, assessment of therapy complications
- Where
- Spain
- Volunteers
- 96 people
- Sponsor
- Institut Català d'Oncologia
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Busulfan, Fludarabine, Clofarabine With Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia
The goal of this clinical research study is to find the best dose of clofarabine and fludarabine that can be given with busulfan followed by an allogeneic blood stem cell transplant.
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndrome, Chronic Myeloid Leukemia
- Trial name
- NCT00469014
- Testing
- Clofarabine, Busulfan, Fludarabine
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- M.D. Anderson Cancer Center
Myelodysplastic Syndrome, Acute Myeloid Leukemia
Dose Finding Study of Post-BMT Decitabine Maintenance Treatment in Higher-risk MDS and MDS/AML
Brief Scientific Rationale: Decitabine has been shown to be effective for treatment of MDS and associated with very limited extramedullary toxicity at the lower doses.
- Trial name
- PODAC (NCT01277484)
- Testing
- Decitabine
- Where
- South Korea
- Volunteers
- 19 people
- Sponsor
- Seoul St. Mary's Hospital
Myelodysplastic Syndromes
Comprehensive Molecular and Clinical Evaluation of Pediatric and Adult MDS
Background: Myelodysplastic syndromes (MDS) occur when the cells that make blood cells are abnormal. There are limited treatment options for MDS.
- Trial name
- NCT05350748
- Where
- United States
- Volunteers
- 1,100 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Acute Myeloid Leukemia
Venetoclax and Decitabine Assessment in Patients (≥60 - <75 Years) with Newly Diagnosed AML Eligible for Allo-SCT
This trial is a no profit, prospective, phase II, multicentre, non-randomised, uncontrolled, single group assignment, open label study to evaluate the safety and efficacy of the "chemo-free" combination Venetoclax plus Decitabine…
- Trial name
- NCT04476199
- Testing
- Venetoclax and Decitabine
- Where
- 25 sites in Italy
- Volunteers
- 100 people
- Sponsor
- Gruppo Italiano Trapianto di Midollo Osseo
Acute Myeloid Leukemia, Acute Myeloid Leukemia Post Cytotoxic Therapy
Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia
This phase I trial studies the side effects and the best dose of bortezomib and sorafenib tosylate when given together with decitabine in treating patients with acute myeloid leukemia.
- Conditions
- Acute Myeloid Leukemia, Acute Myeloid Leukemia Post Cytotoxic Therapy, Recurrent Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia
- Trial name
- NCT01861314
- Testing
- Bortezomib, Decitabine, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Accelerated Phase CML, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia in Remission
CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Transplant
This phase II trial studies how well multi-peptide CMV-modified vaccinia Ankara (CMV-MVA Triplex) vaccination of stem cell donors works in preventing cytomegalovirus (CMV) viremia in participants with blood cancer undergoing…
- Conditions
- Accelerated Phase CML, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission, Chronic Lymphocytic Leukemia
- Trial name
- NCT03560752
- Testing
- Multi-peptide CMV-Modified Vaccinia Ankara Vaccine
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
AML, Adult
A Phase I/II Dose Escalation and Expansion Study of BST-236 Plus Venetoclax in Patients With Unfit Newly Diagnosed AML
An open label multi centre study to assess the safety and efficacy of BST-236 in combination with venetoclax in adult patients unfit for standard therapy with newly diagnosed Acute Myeloid Leukemia (AML) Part 1 of the study will…
- Trial name
- NCT05503355
- Testing
- BST-236, venetoclax
- Where
- 3 sites in United States
- Volunteers
- 80 people
- Sponsor
- BioSight Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.